---
title: "Bernstein Sticks to Its Buy Rating for Innovent Biologics (IVBXF)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299986331.md"
description: "In a report released on September 22, from Bernstein maintained a Buy rating on Innovent Biologics, with a price target of HK$128.00. The company’s shares closed yesterday at HK$103.10. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Innovent Biologics with a HK$132.78 average price target, implying a 28.78% upside from current levels. In a report released on September 15, DBS also reiterated a Buy rating on the stock with a HK$144.00 price target."
datetime: "2026-09-24T06:45:54.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299986331.md)
  - [en](https://longbridge.com/en/news/299986331.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299986331.md)
generator: "portal-rs"
---

# Bernstein Sticks to Its Buy Rating for Innovent Biologics (IVBXF)

In a report released on September 22, from Bernstein maintained a Buy rating on Innovent Biologics, with a price target of HK$128.00. The company’s shares closed yesterday at HK$103.10.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Innovent Biologics with a HK$132.78 average price target, implying a 28.78% upside from current levels. In a report released on September 15, DBS also reiterated a Buy rating on the stock with a HK$144.00 price target.

### Related Stocks

- [01801.HK](https://longbridge.com/en/quote/01801.HK.md)
- [AB.US](https://longbridge.com/en/quote/AB.US.md)
- [D05.SG](https://longbridge.com/en/quote/D05.SG.md)

## Related News & Research

- [Innovent to present phase 3 interim data for CLDN18.2 ADC IBI343 in third-line gastric cancer at ESMO 2026](https://longbridge.com/en/news/299868125.md)
- [Is Innovent Biologics (SEHK:1801) Fairly Valued On LP 003 China BLA Progress?](https://longbridge.com/en/news/299077252.md)
- [Innovent to Present New Clinical Data of Next-gen IO and ADC Pipeline at the 2026 ESMO Annual Meeting](https://longbridge.com/en/news/299868198.md)
- [Innovent Biologics reports 1H results](https://longbridge.com/en/news/296950734.md)
- [Nomura: China's 15th Five-Year Plan for Pharmaceuticals Highlights Innovation and Globalization, Positive for Innovative Drugmakers and CRDMO](https://longbridge.com/en/news/299594707.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**